ATHN 9 is a natural history study to assess the safety of various Von Willebrand Factor (VWF) regimens for different indications (on-demand, surgery and prophylaxis) in adult and pediatric participants with clinically severe congenital VWD.
We are comparing standard in-office postpartum blood pressure monitoring to at-home monitoring for patient diagnosed with hypertensive disorders of pregnancy.
The primary purpose of this study is to compare extended-release buprenorphine (CAM2038) to buprenorphine placed under the tongue (sublingual) in pregnant women with opioid use disorder to see if CAM2038 is as effective as sublingual buprenorphine. We are looking to recruit pregnant women who are between 18-41 years old; are between 6-30 weeks pregnant and are not planning to terminate the pregnancy; have opioid use disorder, and are enrolled or are planning to enroll in outpatient buprenorphine treatment at The Medical University of South Carolina. Participation in the study would last between 13 and 21 months total with up to between about 63-102 total visits, including weekly medication check visits and research visits.
This study will involve 12 babies who have been identified as at risk for withdrawal symptoms after birth. This study will test the feasibility of acupressure as an additional non-invasive, first line treatment for infants experiencing withdrawal symptoms. We will also send a voluntary survey out to the healthcare providers who cared for the infant (nurse, medical doctor, or advanced practice provider (nurse practitioner or physician assistant).
This study aims to show the safety and effectiveness of AMAG-423, an IV medication, in women with severe preeclampsia. The purpose of this study is to see how well AMAG-423 might work to prevent some of the most serious complications in premature babies, as well as improve symptoms of preeclampsia. Women will be admitted with this diagnosis and receive IV medication, AMAG-423, every 6 hours for up to 4 days. Subjects will be followed through out their hospital stay and up until their post partum 6 week check. The only treatment for severe preeclampsia is delivery.
The purpose of this research study is to test the safety and effectiveness of an investigational drug (Solosec) for the treatment of trichomoniasis. Solosec was approved in the United States by the Food and Drug Administration (FDA) in 2017 for the treatment of bacterial vaginosis (BV) in adult women ages 18 years and older. The sponsor would like to gather additional information for the treatment of Solosec in adult women and girls ages 12 years and older diagnosed with trichomoniasis.
Staff at sites who participate in the MUSC Women's Reproductive Behavioral Telehealth (WRBT) Program will be asked to participate in individual interviews or focus groups (group discussions) about their experience with the telemedicine program and fill out surveys. Patients in the WRBT Program will be asked to fill out surveys about their telemedicine experience.
The purpose of this research is to provide the sponsor vaginal and urine samples that the clinician has collected and the subject has self collected in order to study a new test being developed for the detection of Chlamydia trachomatis and
This purpose of this research study is to collect feedback from participants about a web-based program for opioid misuse and opioid use disorder. Participants will be asked to review web-based content and take part in focus groups (group discussions) and individual interviews to provide feedback on the content. The study team is looking for pregnant women or women who have been pregnant in the past 2 years who misuse opioids or have opioid use disorder, as well as obstetric providers who treat pregnant women with opioid misuse and opioid use disorder to participate.
Preeclamptic patients will have an ultrasound done of their eyes, to look at the size of the nerve behind the eye. We will also recruit women without preeclampsia to be a comparison group.